BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Speedel Pharmaceuticals, Inc. 

1661 Route 22 West
P.O. Box 6532
Bridgewater  New Jersey  08807  U.S.A.
Phone: 732-537-2290 Fax: 732-537-2292


SEARCH JOBS




Industry
Pharmaceutical






 Company News
Speedel Pharmaceuticals, Inc. Release: SP100(Tekturna/Rasilex) Demonstrates Potential to Prodtect Kidneys from Damage 6/5/2008 10:28:13 AM    More...
Novartis Corporation (NVS) and Speedel Pharmaceuticals, Inc. at Loggerheads Over Tekturna Royalties 11/16/2007 12:40:40 PM    More...
Speedel Pharmaceuticals, Inc. Release: New Data Highlights Potential of Spp100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension 5/21/2007 10:36:06 AM    More...
Speedel Pharmaceuticals, Inc. Release: Shareholders Approve All Proposals at Annual General Meeting 5/10/2007 12:52:18 PM    More...
Speedel Pharmaceuticals, Inc. Announces Financial Results for First Quarter 2007 5/4/2007 10:41:08 AM    More...
Speedel Pharmaceuticals, Inc. Announces Financial Results For Full Year 2006 3/29/2007 10:30:21 AM    More...
Speedel Stops Current SPP301 Phase III Trial In Diabetic Kidney Disease In The Interests Of Patient Safety 12/19/2006 1:35:18 PM    More...
Speedel Pharmaceuticals, Inc. Begins Phase IIa Trial With Next Generation Renin Inhibitor 10/31/2006 5:05:31 PM    More...
Second Major Milestone For Speedel Pharmaceuticals, Inc. In Its Goal To Develop Renin Inhibitors As Gold Standard Therapy Over The Next Decade 9/28/2006 10:52:09 AM    More...
Abbott Laboratories (ABT) Declines Option For Speedel Pharmaceuticals, Inc. Drug 8/17/2006 8:33:02 AM    More...
1234